Lynch Syndrome Clinical Trial
Official title:
Capsule Endoscopy in Lynch Syndrome for Small Intestinal Tumor Screening
Lynch syndrome (LS), or hereditary nonpolyposis colorectal cancer (HNPCC), is a hereditary disorder characterized by a very high risk of early-onset colorectal and endometrial cancer and an increased risk of other cancers, including cancers of the stomach, ovary, urinary tract, hepatobiliary tract, pancreas and small bowel. This is a national multi-centre study evaluating the yield of small bowel screening using capsule endoscopy (CE) and double balloon enteroscopy (DBE) in Lynch syndrome subjects. The intervention consists of performing a capsule endoscopy procedure at baseline and at 2-year follow-up. In patients with polyps or malignant appearing abnormalities on capsule endoscopy, double balloon enteroscopy will be performed with subsequent endoscopic or surgical removal of neoplastic lesions. The aim of the study is to determine the prevalence and incidence of small bowel neoplasia in Lynch syndrome patients using small bowel CE and DBE.
Lynch syndrome (LS), or hereditary nonpolyposis colorectal cancer (HNPCC), is an autosomal
dominantly inherited disorder characterized by a very high risk of early-onset colorectal
and endometrial cancer and an increased risk of other cancers, including cancers of the
stomach, ovary, urinary tract, hepatobiliary tract, pancreas and small bowel. LS is caused
by germline mutations in one of the mismatch repair (MMR) genes, mostly hMLH1, hMSH2 and
hMSH6. Recently, several studies, including one from the Netherlands, have evaluated the
life-time risk of small bowel cancer (SBC) in LS patients. From these studies the life-time
risk of SBC is estimated around 4%. This is similar to the life-time risk of colorectal
cancer in the general population, for which screening is generally advised. The risk of SBC
increases with age, with an estimated prevalence of 1:500 at the age of 40, rising to an
estimated prevalence of around 1:70 at the age of 60. Compared with the general population,
LS patients with SBC generally present 10-20 years earlier as most patients with sporadic
SBC are in their sixth or seventh decade of life. The localisation of SBC in LS is almost
equal in the duodenum and jejunum, with localisation in the ileum generally occurring at a
lower frequency.Until now, screening for small bowel neoplasia in Lynch syndrome patients is
generally not recommended. However, the development of two new techniques to visualize the
small intestine has raised the question whether screening might be useful and advisable.
Small bowel capsule endoscopy (CE) has been developed as a safe, patient-friendly, minimally
invasive modality for visualization of the small bowel. In addition, double-balloon
enteroscopy (DBE) has been developed, a technique which allows endotherapeutic
interventions. The diagnostic yields of both techniques are markedly higher than the
conventional methods, such as push-enteroscopy and enteroclysis. To date, no study has been
performed on screening for small bowel neoplasia in Lynch syndrome patients by means of
these techniques.
The primary aim of the study is to determine the prevalence and incidence of small bowel
neoplasia in Lynch syndrome patients using small bowel CE and DBE.
Secondary objectives:
The secondary aim is to identify risk factors for small bowel pathology useful in clinical
practice to identify patients that might benefit from screening and to determine the
additional interventional risk associated with the endoscopic procedures.
This is a national multi-centre study evaluating the yield of small bowel screening using
capsule endoscopy and double balloon enteroscopy in Lynch syndrome subjects. The
intervention consists of performing a capsule endoscopy procedure at baseline and at 2-year
follow-up. In patients with polyps or malignant appearing abnormalities on capsule
endoscopy, double balloon enteroscopy will be performed with subsequent endoscopic or
surgical removal of neoplastic lesions.
;
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT00217737 -
Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer
|
Phase 3 | |
Completed |
NCT00905710 -
Chromoendoscopy to Decrease the Risk of Colorectal Neoplasia in Lynch Syndrome
|
N/A | |
Active, not recruiting |
NCT02194387 -
Energy Balance Interventions in Increasing Physical Activity in Breast Cancer Gene Positive Patients, Lynch Syndrome-Positive Patients, CLL Survivors or High-Risk Family Members
|
N/A | |
Recruiting |
NCT04909671 -
Evaluation of ArTificial Intelligence System (Gi-Genius) for adenoMa dEtection in Lynch Syndrome.
|
N/A | |
Recruiting |
NCT04379999 -
Atorvastatin ± Aspirin in Lynch Syndrome Syndrome
|
Early Phase 1 | |
Recruiting |
NCT05692596 -
The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics
|
||
Completed |
NCT01845753 -
Molecular Screening for Lynch Syndrome in Denmark
|
||
Completed |
NCT01216930 -
Molecular Screening for Lynch Syndrome in Southern Denmark
|
N/A | |
Not yet recruiting |
NCT05963191 -
CAD-EYE System for the Detection of Neoplastic Lesions in Patients With Lynch Syndrome
|
N/A | |
Active, not recruiting |
NCT02912559 -
Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
|
Phase 3 | |
Recruiting |
NCT04978350 -
Overcoming Barriers to the Uptake of Cascade Screening for Lynch Syndrome: Workbook Feasibility Study
|
N/A | |
Active, not recruiting |
NCT03832985 -
Pediatric Reporting of Adult-Onset Genomic Results
|
Early Phase 1 | |
Withdrawn |
NCT04778566 -
Evaluating the Cologuard Test for Use in Lynch Syndrome
|
||
Completed |
NCT02570516 -
NBI Versus Indigo Carmine During Colonoscopy in Lynch Syndrome
|
N/A | |
Completed |
NCT01823471 -
I-Scan For Colon Polyp Detection In HNPCC
|
N/A | |
Recruiting |
NCT02813824 -
Effect of Chemoprevention by Low-dose Aspirin of New or Recurrent Colorectal Adenomas in Patients With Lynch Syndrome
|
Phase 3 | |
Recruiting |
NCT05078866 -
Cancer Preventive Vaccine Nous-209 for Lynch Syndrome Patients
|
Phase 1/Phase 2 | |
Recruiting |
NCT03744962 -
MSI in Circulatory DNA of Endometrial Cancer
|
||
Recruiting |
NCT04711434 -
PD-1 Antibody for The Prevention of Adenomatous Polyps and Second Primary Tumors in Lynch Syndrome Patients
|
Phase 3 | |
Completed |
NCT04131062 -
Trial to Compare eConsent With Standard Consent Among Prospective Biobank Participants
|
N/A |